What is AOD9604 and how does it promote lipolysis without GH receptor activation?

AOD9604 is a synthetic modified peptide derived from the C-terminal region of human growth hormone (hGH), specifically corresponding to amino acids 176-191 with a stabilizing tyrosine residue added to the N-terminus. Unlike full-length hGH which activates GH receptors (GHR) causing diverse metabolic effects including lipolysis, muscle growth, and glucose regulation, AOD9604 selectively retains only the lipolytic (fat-burning) activity while lacking GH receptor binding capacity. This selective mechanism occurs because: (1) The hGH molecule contains distinct functional regions - N-terminal region (1-134) mediates GHR binding and activation, while C-terminal region (176-191) contains a separate lipol ...ytic domain independent of GHR. (2) AOD9604's structure (modified 176-191 fragment) preserves the lipolytic pharmacophore but lacks the GHR-binding epitopes concentrated in hGH's N-terminus, preventing GHR activation and avoiding GH's growth-promoting, insulin-antagonistic, and diabetogenic effects. (3) Lipolytic mechanism - AOD9604 directly stimulates adipocyte lipolysis via β3-adrenergic receptor potentiation and activation of hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), catalyzing triglyceride hydrolysis into free fatty acids and glycerol for oxidation. (4) Fat oxidation enhancement - increases fatty acid β-oxidation in mitochondria, shifting metabolism toward lipid utilization. (5) Selectivity advantage - by avoiding GHR activation, AOD9604 provides targeted adipose tissue effects without affecting glucose metabolism, insulin sensitivity, IGF-1 production, or bone/muscle growth - unlike full hGH which modulates all these pathways creating complex metabolic consequences. Research applications include selective lipolysis mechanisms, adipocyte β3-adrenergic signaling, lipase enzyme regulation, obesity and metabolic syndrome models, comparative GH fragment studies (AOD9604 vs GH Fragment 176-191 vs full hGH), pharmaceutical development of selective anti-obesity agents, and dissecting GH's diverse functions into separable activities. AOD9604's GHR-independent lipolysis makes it uniquely valuable for fat metabolism research without confounding growth or glucose effects.

How does AOD9604 compare to full-length GH and Fragment 176-191?

AOD9604, GH Fragment 176-191, and full-length hGH represent a continuum of GH-derived peptides with progressively different activities: (1) AOD9604 vs Fragment 176-191 - structurally very similar; AOD9604 is Fragment 176-191 with a stabilizing N-terminal tyrosine modification enhancing peptide stability and half-life while retaining identical lipolytic mechanism; both lack GHR binding and selectively stimulate lipolysis. (2) AOD9604 vs full hGH - fundamentally different mechanisms: full hGH activates GHR triggering JAK-STAT signaling producing lipolysis plus muscle growth, bone growth, IGF-1 production, insulin antagonism, and glucose elevation; AOD9604 stimulates lipolysis via GHR-independent adipocyte lipase activation without growth, IGF-1, or glucose effects. (3) Lipolytic potency - AOD9604 shows comparable or enhanced lipolytic activity vs full hGH in adipocyte assays (measured by free fatty acid/glycerol release) despite lacking GHR activation, demonstrating the C-terminal 176-191 region contains potent intrinsic lipolytic pharmacophore. (4) Safety profile - AOD9604 avoids full hGH's adverse effects: no hyperglycemia risk (hGH antagonizes insulin), no acromegaly/gigantism concerns (hGH stimulates bone/soft tissue growth), no IGF-1 elevation (hGH induces hepatic IGF-1 production which has separate metabolic/growth effects). (5) Half-life - AOD9604's tyrosine modification extends half-life vs unmodified Fragment 176-191, but both are shorter-lived than full hGH; enables more controllable lipolytic stimulation. (6) Research applications - AOD9604/Fragment 176-191 ideal for selective lipolysis research and dissecting GH's multiple functions into separable activities; full hGH for comprehensive GH receptor biology and integrated growth/metabolic studies. (7) Specificity - AOD9604 provides clean lipolytic signal without confounding GHR-mediated growth, anabolic, or diabetogenic effects, simplifying mechanistic fat metabolism research. Choose AOD9604 for targeted adipocyte lipolysis studies; choose full hGH for GH receptor pharmacology and systemic GH biology.

What purity and quality standards does your AOD9604 meet?

Our AOD9604 exceeds >98% purity verified by HPLC with comprehensive quality control for this modified GH-derived lipolytic peptide. Each batch undergoes: reverse-phase HPLC demonstrating >98% purity with retention time characteristic of the modified 176-191 fragment, mass spectrometry molecular weight confirmation for AOD9604 including the stabilizing N-terminal tyrosine modification (expected mass ~1846 Da for the synthetic peptide), peptide sequence verification confirming amino acid 176-191 sequence from hGH C-terminus plus N-terminal tyrosine via MS/MS fragmentation or Edman degradation, modification validation ensuring proper tyrosine conjugation for stability enhancement, lipolysis bioassays - the gold standard measuring AOD9604's ability to stimulate free fatty acid and glycerol release from adipocytes (primary adipocytes or differentiated 3T3-L1 cells treated with AOD9604, quantifying lipolytic products via ELISA or colorimetric assays), dose-response characterization establishing EC50 for lipolytic stimulation, GH receptor non-binding verification confirming AOD9604 lacks GHR activation (negative results in GHR binding assays and absence of JAK-STAT signaling vs full hGH's robust GHR activation), comparative lipolytic potency vs Fragment 176-191 and full hGH demonstrating selective fat-mobilizing activity, endotoxin testing ( 98% purity ensures reproducible lipolytic stimulation, consistent adipocyte responses, and reliable fat metabolism research without interference from synthesis impurities or unmodified fragments. Quality control validates both chemical identity (correct sequence with tyrosine modification) and biological function (adipocyte lipolysis without GHR activation) essential for selective fat metabolism investigations. The GHR-independent lipolytic activity is particularly important to verify - distinguishing AOD9604's direct adipocyte effects from full hGH's GHR-mediated mechanisms, ensuring researchers study isolated lipolytic pathways without confounding growth hormone receptor signaling.

What research applications benefit from AOD9604's selective lipolysis?

AOD9604 excels in research requiring isolated adipocyte lipolytic stimulation without GH receptor activation: adipocyte lipolysis mechanisms investigating hormone-sensitive lipase (HSL), adipose triglyceride lipase (ATGL), and perilipin regulation - AOD9604 activates these lipases triggering triglyceride hydrolysis into free fatty acids and glycerol for β-oxidation; β3-adrenergic signaling research examining how AOD9604 potentiates β3-adrenergic receptors on adipocytes enhancing cAMP-PKA-mediated lipase activation; fat oxidation pathway studies measuring fatty acid β-oxidation rates in mitochondria, carnitine palmitoyltransferase-1 (CPT-1) activity, and metabolic shift toward lipid utilization upon AOD9604 treatment; obesity and metabolic syndrome models using AOD9604 to stimulate fat mobilization and weight reduction without affecting glucose metabolism, insulin sensitivity, or lean mass (unlike full hGH); comparative GH fragment research evaluating AOD9604 vs Fragment 176-191 vs full hGH to dissect which hGH activities are GHR-dependent vs independent, mapping functional domains; pharmaceutical development of selective anti-obesity agents targeting adipose tissue without diabetogenic or growth-promoting effects; body composition research investigating preferential fat mass reduction while preserving muscle mass (AOD9604's lack of anabolic GHR effects means no muscle hypertrophy, isolating fat loss); adipocyte biology using AOD9604 as selective lipolytic stimulus to study lipid droplet dynamics, perilipin phosphorylation, and lipase translocation without confounding GHR-STAT5 transcriptional effects; metabolic syndrome research examining whether isolated lipolysis improvement (without GHR activation) benefits insulin resistance or requires GH's additional effects; and mechanistic dissection of how GH's C-terminal region (176-191) stimulates lipolysis independently of GHR. AOD9604's selective mechanism enables clean lipolytic studies eliminating GHR-mediated growth, IGF-1, and glucose confounders, ideal for focused adipose tissue research and obesity therapeutic development.

How should AOD9604 be stored and reconstituted?

Store lyophilized AOD9604 at -20°C in original sealed vials for 24+ months stability. The modified peptide with N-terminal tyrosine maintains excellent stability when lyophilized and frozen. Reconstitute by adding sterile water, bacteriostatic water (0.9% benzyl alcohol), or sterile saline slowly down the vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 0.5-2 mg/mL. AOD9604 dissolves readily; allow 1-2 minutes for complete dissolution. Refrigerate reconstituted solution at 2-8°C and use within 14 days for maximum lipolytic bioactivity. The modified peptide shows enhanced stability vs unmodified Fragment 176-191 (N-terminal tyrosine protects against aminopeptidase degradation) but aqueous solutions still degrade over time via oxidation and deamidation. Bacteriostatic water extends stability by preventing bacterial growth. Avoid multiple freeze-thaw cycles which can cause peptide aggregation and loss of lipolytic activity. For multi-week fat metabolism studies, aliquot reconstituted solution into single-use sterile vials immediately after reconstitution, storing aliquots at -20°C and thawing fresh aliquot for each experiment (accepting one freeze-thaw). pH considerations: AOD9604 is most stable near neutral pH (6.5-7.5); avoid highly acidic or basic conditions. Light protection: store in amber vials or wrap in foil as tyrosine residues can undergo photodegradation. Proper storage ensures consistent adipocyte lipolytic stimulation, reproducible free fatty acid/glycerol release assays, and reliable selective fat metabolism research. The tyrosine modification enhances stability enabling extended study protocols compared to unmodified GH fragments while maintaining selective lipolytic activity without GHR activation - ideal for chronic adipose tissue research where frequent peptide replenishment would be impractical.

What makes AOD9604 unique for obesity and fat metabolism research?

AOD9604 offers distinctive advantages for adipose tissue research: (1) Selective lipolysis - stimulates fat breakdown via direct adipocyte lipase activation (HSL, ATGL) without GH receptor engagement, providing isolated lipolytic signal absent in full hGH (which simultaneously affects growth, glucose, IGF-1). (2) No hyperglycemic effects - full hGH antagonizes insulin and elevates blood glucose (diabetogenic potential); AOD9604 lacks GHR activation eliminating glucose metabolism interference, enabling fat loss studies without confounding insulin resistance or hyperglycemia. (3) Preserved lean mass - full hGH's GHR activation produces anabolic muscle growth potentially confounding body composition studies; AOD9604's GHR-independence means lipolysis without muscle hypertrophy, isolating fat mass reduction. (4) No IGF-1 elevation - full hGH induces hepatic IGF-1 production with separate metabolic and growth effects; AOD9604 avoids this, simplifying mechanistic interpretation. (5) Safety for chronic studies - full hGH's growth-promoting and diabetogenic effects limit long-term experimental use; AOD9604's selective mechanism enables extended obesity research protocols without acromegaly, hyperglycemia, or insulin resistance risks. (6) Mechanistic tool - by providing GH's lipolytic activity without its GHR-dependent effects, AOD9604 helps dissect which obesity benefits derive from direct adipocyte lipolysis vs indirect GHR-IGF-1 pathways. (7) β3-adrenergic potentiation - AOD9604 enhances β3-adrenergic receptor signaling in adipocytes, revealing synergistic interactions between GH-derived lipolytic factors and adrenergic systems. (8) Pharmaceutical development - models selective anti-obesity agents targeting fat mobilization without growth/glucose side effects, guiding therapeutic design. (9) Dose-response characterization - easier to establish lipolytic dose-response without interference from GHR-mediated pleiotropic effects. AOD9604's GHR-independent selective lipolysis makes it the premier tool for clean adipocyte fat metabolism research, obesity mechanism studies, and anti-obesity therapeutic development where full hGH's complex multi-system effects would confound interpretation.

What dosage specifications and bulk pricing are available for AOD9604?

We offer three AOD9604 specifications: 2AD (2mg per 10-vial kit), 5AD (5mg per 10-vial kit), 10AD (10mg per 10-vial kit). Pricing with bulk discounts: 2AD: $90/kit (1 kit), $90/kit (20+ kits = 0% discount, pricing already optimized), $85/kit (50+ kits = 5.6% discount). 5AD: $180/kit (1 kit), $175/kit (20+ kits = 2.8% discount), $170/kit (50+ kits = 5.6% discount). 10AD: $320/kit (1 kit), $315/kit (20+ kits = 1.6% discount), $310/kit (50+ kits = 3.1% discount). The three concentration options accommodate diverse research from pilot adipocyte lipolysis assays and dose-response characterization to extensive chronic obesity model studies and comparative GH fragment research. Pricing reflects specialized synthesis of the modified C-terminal GH fragment (amino acids 176-191) with stabilizing N-terminal tyrosine conjugation, rigorous quality control (HPLC purity, mass spec modification verification, adipocyte lipolysis bioassays, GHR non-binding confirmation), and comprehensive CoA documentation - while maintaining >98% purity essential for reproducible selective lipolytic research. Bulk discounts at 20+ and 50+ kits support large-scale obesity research programs, body composition studies requiring extended treatment protocols, comparative GH fragment investigations, institutional metabolic research centers, and pharmaceutical anti-obesity therapeutic development. For academic adipose tissue biology labs, pharmaceutical companies developing selective lipolytic agents, obesity research departments investigating fat metabolism independent of growth effects, biotechnology firms formulating body composition therapeutics, or international metabolic syndrome research consortia, contact via WhatsApp to discuss custom quantity requirements, specific concentration needs, or volume pricing. AOD9604's unique GHR-independent lipolytic mechanism makes it essential for selective fat metabolism research worldwide, enabling adipocyte studies without the complex multi-system effects of full growth hormone confounding mechanistic interpretation.

How do you validate AOD9604's lipolytic bioactivity and GHR non-activation?

Beyond chemical purity (HPLC >98%, mass spec confirming sequence with tyrosine modification), we perform dual validation: confirming lipolytic activity while verifying GHR non-activation - both critical for AOD9604's selective mechanism: (1) Adipocyte lipolysis bioassays - the gold standard using primary adipocytes isolated from rodent epididymal fat pads or differentiated 3T3-L1 adipocytes treated with varying AOD9604 concentrations, measuring free fatty acid (FFA) and glycerol release into culture media via ELISA or colorimetric assays (glycerol release quantifies triglyceride hydrolysis), establishing dose-response curves and EC50 for lipolytic stimulation. (2) Lipase activation - Western blot or enzyme activity assays measuring AOD9604-induced activation (phosphorylation) of hormone-sensitive lipase (HSL Ser660 phosphorylation) and adipose triglyceride lipase (ATGL), demonstrating mechanism of triglyceride hydrolysis. (3) Perilipin phosphorylation - measuring AOD9604-stimulated perilipin-1 phosphorylation (facilitates lipase access to lipid droplets) via immunoblotting, confirming complete lipolytic signaling cascade. (4) β3-adrenergic potentiation assays - co-treatment studies showing AOD9604 enhances β3-adrenergic agonist-stimulated lipolysis (synergistic effect), revealing receptor interaction mechanisms. (5) GH receptor binding assays - critical negative control using GHR-expressing cells or receptor binding assays demonstrating AOD9604 fails to bind GHR (unlike full hGH showing robust binding), confirming lack of receptor activation. (6) JAK-STAT signaling - measuring STAT5 phosphorylation (downstream of GHR activation); full hGH induces strong pSTAT5, while AOD9604 shows no STAT5 activation, validating GHR-independent mechanism. (7) IGF-1 non-induction - treating hepatocytes or measuring serum IGF-1; full hGH elevates IGF-1 via GHR, AOD9604 does not, confirming lack of GHR pathway engagement. (8) Comparative potency - side-by-side testing AOD9604 vs Fragment 176-191 vs full hGH showing AOD9604's lipolytic activity matches or exceeds hGH despite lacking GHR activation. CoA includes adipocyte lipolysis dose-response curves (FFA/glycerol release), lipase activation data, GHR binding results (negative), and STAT5 signaling confirmation (absent) - ensuring AOD9604's selective lipolytic bioactivity without GHR-mediated confounders.

Can AOD9604 be combined with other metabolic peptides for research?

Yes! AOD9604 combinations enable investigating multi-pathway fat metabolism regulation: (1) AOD9604 + full hGH - comparing selective lipolysis (AOD9604 via GHR-independent adipocyte lipase activation) vs comprehensive GH effects (full hGH via GHR producing lipolysis plus muscle growth, IGF-1, glucose elevation); dissects GHR-dependent vs independent components of hGH's metabolic actions. (2) AOD9604 + Fragment 176-191 - both share lipolytic mechanism but AOD9604 has tyrosine modification enhancing stability; comparative studies validate whether modification alters potency or selectivity. (3) AOD9604 + CJC-1295/Ipamorelin - combining direct lipolytic stimulation (AOD9604) with endogenous GH secretion (GH secretagogues), investigating whether stimulating endogenous GH produces different fat metabolism vs direct GH fragment administration. (4) AOD9604 + thyroid hormones (T3/T4) - additive or synergistic fat oxidation from independent mechanisms (AOD9604 lipase activation + thyroid hormone-induced metabolic rate/mitochondrial uncoupling); obesity research combining lipolysis with thermogenesis. (5) AOD9604 + β3-adrenergic agonists - potentiated lipolysis exploiting AOD9604's enhancement of β3-adrenergic signaling, maximizing cAMP-PKA-lipase cascade. (6) AOD9604 + AMPK activators (metformin, AICAR) - combining lipolysis (AOD9604) with fatty acid oxidation stimulation (AMPK → CPT-1 → enhanced β-oxidation), complete fat mobilization and utilization pathway. (7) AOD9604 + insulin sensitizers - addressing whether isolated lipolysis (without GHR's insulin-antagonistic effects) improves insulin sensitivity vs full hGH which can worsen glucose tolerance. (8) AOD9604 + leptin - investigating interactions between lipolysis and satiety/energy expenditure regulation. These combinations dissect obesity's multi-factorial mechanisms, reveal pathway interactions, and guide pharmaceutical development of combination anti-obesity therapies targeting complementary metabolic processes for synergistic fat reduction.

What documentation and shipping support AOD9604 fat metabolism research globally?

We ship AOD9604 in lyophilized form with cold pack insulation in sealed packaging. Lyophilized modified peptide remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation during international transit. International delivery typically takes 10-14 days with tracking; upon arrival immediately transfer to -20°C storage. Each batch includes comprehensive Certificate of Analysis documenting selective lipolytic quality: HPLC chromatogram demonstrating >98% purity with retention time characteristic of the modified GH fragment (176-191 with N-terminal tyrosine), mass spectrometry data confirming molecular weight (~1846 Da) and sequence identity including tyrosine modification via MS/MS fragmentation, peptide sequence verification confirming amino acids 176-191 from hGH C-terminus plus stabilizing N-terminal tyrosine, modification characterization validating proper tyrosine conjugation for enhanced stability, adipocyte lipolysis bioassay results demonstrating dose-dependent free fatty acid and glycerol release (measured via ELISA/colorimetric assays) with EC50 potency quantification, lipase activation data showing HSL and ATGL phosphorylation/activation confirming mechanism, GH receptor binding assay results (negative control) proving AOD9604 lacks GHR activation unlike full hGH, STAT5 signaling confirmation (absence of pSTAT5) validating GHR-independent mechanism distinguishing AOD9604 from hGH's receptor-mediated effects, comparative lipolytic potency vs Fragment 176-191 and full hGH demonstrating selective activity, endotoxin testing results (<0.1 EU/mg), batch number and manufacturing date for traceability, storage recommendations (lyophilized: -20°C long-term 24+ months; reconstituted: 2-8°C refrigerated for 14 days with enhanced stability from tyrosine modification), and reconstitution protocols for adipocyte lipolysis research. This documentation satisfies institutional requirements and critically validates AOD9604's dual characteristics: potent lipolytic bioactivity (adipocyte lipase activation, FFA/glycerol release) AND GHR non-activation (negative GHR binding, no STAT5 signaling) - both essential for selective fat metabolism research. The comprehensive CoA enables researchers to cite validated selective lipolytic specifications ensuring reproducible obesity and adipose tissue studies worldwide without GH receptor confounders.

Home ProductsAOD9604

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

AOD2

AOD9604

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade AOD9604 for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $205/kit

+$190

extra savings

Total Price

$300

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.11% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

AOD9604: Key Facts

AOD9604 is a fat loss research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 3 formats starting at $300 per kit. Each batch is independently HPLC-verified at 99.11% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	AOD9604
Research category	Fat Loss
Available formats	2mg10vials, 5mg10vials, 10mg*10vials
Starting price	From $300 USD per kit
Purity	99.11% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Priya Malhotra

New Zealand

"Our metabolic research lab at a clinical research team in Chandigarh has been using LyzeLabs AOD9604 for selective lipolysis studies for 10 months. The pharmaceutical quality is exceptional - we independently verified >98.7% purity via HPLC and mass spec confirmed the modified GH fragment with N-terminal tyrosine (molecular weight 1847.3 Da matching theoretical). Our research investigates AOD9604's GHR-independent fat metabolism - differentiated 3T3-L1 adipocyte bioassays show robust dose-dependent glycerol and free fatty acid release (colorimetric/ELISA quantification) with EC50 ~0.4 µM, confirming potent lipolytic activity. We validated GHR non-activation using GHR-expressing cells - AOD9604 produces zero STAT5 phosphorylation (Western blot) vs full hGH's strong pSTAT5 signal, demonstrating selective mechanism. Lipase activation assays show AOD9604 induces HSL Ser660 phosphorylation and ATGL activation comparable to β3-adrenergic agonists, validating triglyceride hydrolysis mechanism. The critical advantage is selective lipolysis without hGH's hyperglycemic effects - glucose tolerance tests in rodent obesity models show AOD9604 reduces fat mass without impairing insulin sensitivity (unlike full hGH which antagonizes insulin). We measured enhanced fatty acid β-oxidation (Seahorse analysis) confirming AOD9604 shifts metabolism toward lipid utilization. The 2AD and 5AD specifications support our dose-response and chronic obesity protocols perfectly. Delivery to Punjab takes 11-13 days with cold-chain packaging. Premier selective lipolytic peptide for international metabolic research."

2025-11-16

Carlos H.

United States

"Repeatable quality. That matters more than any one good order."

2025-11-13

Erik J.

Denmark

"HPLC read lined up with the posted COA. Reordered."

2025-11-10

About This Product

AOD9604 Research Guide

The HGH Fragment Without the Growth Effect

AOD9604 is a 15 amino acid modified fragment of the C-terminus of human growth hormone, specifically corresponding to amino acids 177-191 of the native HGH molecule with a disulfide bridge modification. It was developed by isolating the lipolytic (fat-mobilizing) effect of growth hormone from its anabolic and glucose-handling effects.

Native HGH produces lipolysis as one of several downstream effects, but also drives IGF-1 production, protein synthesis, and glucose metabolism changes that confound research focused specifically on fat metabolism. AOD9604 retains the lipolytic signal without meaningfully activating the IGF-1 axis or the broader anabolic pathway, making it a cleaner research tool for isolated lipolysis studies.

Mechanism

Lipolysis activation: drives triglyceride breakdown in adipose tissue through a mechanism that parallels native HGH's fat-mobilizing effect
Beta-3 adrenergic receptor signaling: some research suggests overlap with the beta-3 adrenergic pathway involved in brown adipose activation
No meaningful IGF-1 induction: unlike full-length HGH, AOD9604 does not drive hepatic IGF-1 production in the same way, which isolates the fat metabolism signal from the broader anabolic cascade
Does not affect glucose metabolism like full HGH: another mechanistic isolation that makes it useful for research on fat-specific pathways

Research Applications

Isolated lipolysis research where HGH's other effects would confound the measurement
Comparative research against full-length [HGH 191AA](/product/hgh-191aa) to separate lipolytic from anabolic effects
Fat metabolism pharmacology studies
Adipose tissue research involving beta-3 adrenergic pathways
Metabolic research in combination with other fat-loss compounds

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Form: lyophilized powder in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For research purposes only. Not for human consumption or therapeutic use.

Research Context for AOD9604

Lipolysis and Fat Metabolism Research Context

Fat metabolism research peptides target lipolysis, mitochondrial fatty acid oxidation, brown adipose activation, or direct effects on adipocyte viability. Research protocols measure body composition, lipid panel markers, and tissue-specific fat mobilization under defined experimental conditions.

AOD9604 ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Fat Loss category, with 3 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Fat Loss Category

Research Tools for This Compound

Frequently Asked Questions

AOD9604

$300